ArticleInternational journal of reproductive biomedicine2026
Oral dydrogesterone versus oral micronized progesterone: Interim analysis of a randomized controlled trial in pregnant women with threatened miscarriage.
Article in International journal of reproductive biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Progestogen/progestin supplementation is favorable in threatened miscarriage. However, comparative data on the efficacy, safety, and immunomodulatory functions of types/routes of administration are limited. Objective: This study compares oral dydrogesterone (DYD) vs. oral micronized progesterone (MP) in threatened miscarriage. Materials and Methods: This ongoing, investigator-initiated, randomized controlled trial includes eligible, consenting, pregnant women who had vaginal bleeding and/or abdominal pain during first trimester. Participants are treated up to 14 gestational wk with DYD (40 mg stat followed by 10 mg thrice daily) or MP (200 mg twice daily). The following outcomes till 20 gestational wk are presented: miscarriage rate (primary); change in serum cytokines (interferon gamma [IFN- Results: Interim analysis includes 116 participants (DYD, 62; MP, 54). Miscarriage rate in DYD (14.52%) was statistically comparable to, but numerically lower than, that in MP (20.37%; p = 0.558). The mean time to symptom resolution in DYD and MP was, respectively, 6.49 and 7.38 days for vaginal bleeding, and 7.15 and 7.67 days for abdominal pain. Numerically, IFN- Conclusion: Compared to oral MP, oral DYD resulted in a numerically lower miscarriage rate and time to symptom resolution, concomitant to favorable decrease in Th1:Th2 ratio.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.